SRR1335029
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1490382 | GTEX | — | 0.987 |
| 2 | SRR1472621 | GTEX | — | 0.981 |
| 3 | SRR1421140 | GTEX | — | 0.979 |
| 4 | SRR1456841 | GTEX | — | 0.979 |
| 5 | SRR1322270 | GTEX | — | 0.978 |
| 6 | SRR1476632 | GTEX | — | 0.978 |
| 7 | SRR1355061 | GTEX | — | 0.978 |
| 8 | SRR1321244 | GTEX | — | 0.975 |
| 9 | SRR1074164 | GTEX | — | 0.975 |
| 10 | SRR1486741 | GTEX | — | 0.975 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| DNA_REPAIR | 0.129 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.124 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.113 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.071 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.053 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.044 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.042 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.035 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.018 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.008 | Inavolisib | — uncovered |